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KEY POINTS SUMMARY
• Although diarrhoeal diseases represent a great health and economic burden to society, therapeutic options remain limited.
• While several bile acids are known to stimulate epithelial Cl -secretion, the major driving force for fluid secretion in the intestine, the effects of ursodeoxycholic acid (UDCA) on epithelial transport function are not known.
• We report that in contrast to other bile acids, UDCA exerts antisecretory actions on colonic epithelial cells in vitro.
• In contrast, in vivo administration of UDCA enhances epithelial secretory function, an affect we ascribe to being due to its bacterial metabolism to lithocholic acid (LCA). In keeping with this hypothesis, in vivo administration of a metabolically stable analogue of UDCA, 6-methyl-UDCA, was antisecretory.
• Our findings reveal a novel antisecretory effect of UDCA and suggest that metabolically stable analogues the bile acid may be useful for development as a new class of anti-diarrhoeal drug.
Word Count: 148
T 84 cells with bilateral UDCA attenuated Cl -secretory responses to the Ca 2+ and cAMPdependent secretagogues, carbachol (CCh) and forskolin (FSK) to 14.0 ± 3.8% and 40.2 ± 7.4% of controls, respectively (n = 18; p < 0.001). An investigation of molecular targets involved revealed that UDCA acts by inhibiting Na + /K + -ATPase activity and basolateral K + channel currents, without altering their cell surface expression. In contrast, intraperitoneal administration of UDCA (25 mg/kg) to mice enhanced agonist-induced colonic secretory responses, an effect we hypothesised to be due to bacterial metabolism of UDCA to lithocholic acid (LCA). Accordingly, LCA (50-200 M) enhanced agonistinduced secretory responses in vitro and a metabolically stable UDCA analogue, 6-methyl-UDCA (6-MUDCA), exerted antisecretory actions in vitro and in vivo. In conclusion, UDCA exerts direct antisecretory actions on colonic epithelial cells and metabolically stable derivatives of the bile acid may offer a new approach for treating intestinal diseases associated with diarrhoea.
Abbreviations: 4-PB, 4-phenylbutyrate; 6-MUDCA-methyl-UDCA; CCh, carbachol; CDCA, chenodeoxycholic acid; CFTR, cystic fibrosis transmembrane conductance regulator; FSK, forskolin; I sc , short-circuit current; LCA, lithocholic acid;
UDCA, ursodeoxycholic acid
INTRODUCTION
Appropriate regulation of intestinal epithelial fluid and electrolyte transport is important for normal digestive function, mucosal protection, and whole body fluid homeostasis.
Under normal circumstances fluid absorption, driven mainly by Na + absorption, predominates. However, fluid secretion, driven by Cl -secretion, also occurs and is important for lubricating and protecting the mucosa (Barrett & Keely, 2000) . The balance between absorption and secretion is highly dynamic and is regulated by an array of neuronal, immunological, and hormonal messengers. Many intestinal disorders exist that perturb the balance between absorption and secretion leading to the onset of diarrhoea.
While infectious diarrhoea is responsible for ~ 2 million child deaths each year in developing countries, common causes of diarrhoea in Western societies include intestinal pathogens, inflammatory diseases, irritable bowel syndrome, and digestive and metabolic disorders. However, even though the social and economic burdens of such diseases are immense (Sandler et al., 2002) , there are still relatively few safe and effective therapeutic options for their treatment.
At the molecular level, intestinal fluid secretion is co-ordinated by the activity of several transport proteins (Barrett & Keely, 2000) . Energy for the process comes from the activity of basolateral Na + /K + ATPase pumps which maintain low intracellular Na in the liver, stored in their conjugated forms in the gallbladder, and are released into the duodenum upon ingestion of food. As they pass through the small intestine, bile acids facilitate the digestion and absorption of lipids, and are reabsorbed in the terminal ileum to be recycled back to the liver. Normally, this enterohepatic circulation of bile acids is extremely efficient with < 5% of circulating bile acids entering into the colon with each cycle. Here, they are metabolised by resident bacteria, primarily by deconjugation, dehydroxylation and epimerisation, to yield secondary bile acids. Cholic acid is metabolised to deoxycholic acid (DCA), while CDCA is metabolised to ursodeoxycholic acid (UDCA), which is then further metabolised to lithocholic acid (LCA) (Hofmann, 2009) .
Previous studies have shown that conjugated and unconjugated bile acids rapidly induce colonic epithelial Cl -secretion (Volpe & Binder, 1975; Chadwick et al., 1979; Dharmsathaphorn et al., 1989; Potter et al., 1991; Gelbmann et al., 1995; Mauricio et al., 2000; Venkatasubramanian et al., 2001; Moschetta et al., 2003) . While there are considerable species differences in the potencies of different bile acids, it is clear that in humans, prosecretory effects occur only when bile acid levels enter the pathophysiological range (Mekhjian & Phillips, 1970) . Such prosecretory effects are thought to underlie the diarrhoea that is associated with conditions of bile acid malabsorption. Mechanisms by which bile acids stimulate Cl -secretion have been wellstudied in vitro, with both Ca 2+ -and cAMP-dependent mechanisms being implicated (Dharmsathaphorn et al., 1989; Devor et al., 1993; Huang et al., 1995; Moschetta et al., 2003) . Furthermore, it appears that bile acids can exert their prosecretory effects either by acting directly on epithelial cells themselves, or through stimulation of regulatory cells within the mucosa (Karlstrom et al., 1986; Gelbmann et al., 1995) .
Notably, there are strict structure-activity requirements for bile acids in promoting secretion, with only dihydroxy bile acids, such as DCA and CDCA, being effective Apical Cl -currents were measured as previously described (Rochwerger et al., 1994) .
METHODS

Chemicals
Briefly, cell monolayers were mounted in Ussing chambers under an apical to basolateral Cl -gradient (119.8-4.8 mM), established by replacing NaCl in the basolateral solution with equimolar Na-gluconate. Monolayers were basolaterally permeabilised with nystatin (100 g/ml), and after a 35 min re-equilibration period, cells were stimulated with forskolin (FSK; 10 M). Under these conditions, changes in I sc reflect apical Cl -currents
Basolateral K + currents were analyzed as previously described (Kirk & Dawson, 1983 ).
Voltage-clamped T 84 monolayers were apically permeabilised using amphotericin B (50 M Na + /K + -ATPase activity was measured as described by Lam et al. (Lam et al., 2003) . T For measurements of sodium glucose co-transporter (SGLT-1) activity in mice, whole thickness sections of proximal jejunum were mounted in Ussing chambers and bathed apically in glucose-free Ringers, containing mannitol (5 mM), and basolaterally in normal Ringers solution. To stimulate SGLT-1 activity, 25 mM glucose was added apically, with 25 mM mannitol being added basolaterally at the same time to maintain isosmolarity, and changes in I sc were measured. 1mM phloridzin was used to confirm increases in I sc were due to SGLT-1 activity (Grubb, 1995) .
Measurements of Caecal Bile Acids:
Caecal contents were collected from treated and control animals and stored in isopropanol at -20 0 C. Caecal bile acid levels were measured using HPLC-ES-MS/MS and the qualitative caecal bile acid composition was expressed as % total bile acid content, as previously described (Tadano et al., 2006) .
Cell Surface Biotinylation:
The protocol used was based on one previously published (Del Castillo et al., 2005) . Following treatment, cells were washed with ice-cold PBS.
Freshly prepared biotinylation buffer (1mg/ml Sulfo-NHS-Biotin in PBS) was added basolaterally and cells were incubated at 4 0 C for 15 minutes on a rotating platform after which the buffer was replenished. After another 15 mins, cells were washed, incubated with quenching reagent (100 mM glycine), lysed (Triton lysis buffer; 45 mins), and centrifuged (15,300 g, 6 mins). After normalising for protein concentration, supernatants were then precipitated overnight on a rotator at 4 0 C with 100 L of streptavidin-agarose beads (Pierce Biotechnology, Rockford, IL, USA). Biotinylated proteins were detected by western blotting.
Western Blotting: T 84 monolayers were washed with ice-cold PBS and lysed (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris Base, 1 Complete mini EDTA-free protease inhibitor tablet, 0.1 mg/ml PMSF and 1 mM Na 3 VO 4 ). Lysates were sonicated, centrifuged (15,300 g; 10 min; 4°C), and the pellet discarded. After normalising for protein content, 2x gel loading buffer (50 mM Tris HCl, 100 mM DTT, 40% glycerol, 4% SDS) was added, and samples were then separated by SDS-PAGE, followed by transfer to PVDF membranes. Membranes were preblocked in 5% blocking buffer (Marvel in Tris-buffered saline with 1% Tween (TBST)) for 60 min at room temperature, followed by incubation with primary antibody in blocking buffer overnight at 4°C. The primary antibodies employed were anti-Na + /K + ATPase   subunit antibodies (mouse, 1:10,000dilution), anti-KCNN4 antibodies (rabbit; 1:1500 dilution), and anti--actin (1:10000 dilution.
After washing (x4) in TBST, membranes were incubated with HRP-conjugated secondary antibodies (1:3000 dilution) in blocking buffer for 60 min at room temperature. After further washing (x4) in TBST, immunoreactive proteins were detected by enhanced chemiluminescence (Amersham Biosciences, Little Chalfont, UK).
Statistical Analysis: Results are expressed as mean ± SEM for a series of n experiments.
Statistical analyses were performed by paired t-tests or ANOVA with the Tukey multiple comparisons test, as appropriate (Instat Software; GraphPad, San Diego, CA). p values ≤ 0.05 were considered to be significant. The effects of UDCA on voltage-clamped human colonic tissue were also examined.
RESULTS
UDCA exerts antisecretory actions on colonic epithelial cells in vitro.
After mounting in Ussing chambers, tissues were first treated with tetrodotoxin (TTX) to remove the possible influence of enteric nerves. Similar to our findings in cultured epithelial cells, UDCA alone was without effect on basal I sc (data not shown), but significantly attenuated subsequent agonist-induced responses in a concentrationdependent manner ( Figure 1D ).
To determine effects of UDCA on electrogenic Na + absorption through ENaC, a previously published approach was employed to induce ENaC expression in T 84 cells (Iordache and Duszyk, 2007) . Pretreatment of cells with 4-phenylbutyrate (4-PB) for 24 hrs induced ENaC protein expression (data not shown) and a basal I sc of 7.7 ± 0.1 A/cm 2 . While this 4-PB-induced current was abolished by the ENaC blocker, amiloride (10 M), treatment with UDCA (500 M) was without effect ( Figure 1E ).
In vivo administration of UDCA enhances colonic secretory responses in mice. To examine effects of UDCA administration in vivo, mice were injected intraperitoneally with UDCA (25 mg/kg), and after 4 hrs their colons were removed, stripped of smooth muscle, and mounted in Ussing chambers for I sc measurements. Interestingly, in direct contrast to its antisecretory effects in cultured epithelia, UDCA enhanced secretagogueinduced responses in ex vivo colonic tissues (Figure 2A ). We hypothesised that such contrasting effects could be due to bacterial metabolism of UDCA to LCA in vivo. This hypothesis was supported by our findings that colonic LCA levels were significantly increased in UDCA-treated mice from 9.7 ± 1.6 nmol/g (4% of total BA) to 33.4 ± 6.5 nmol/g (16% of total BA) in UDCA-treated mice ( Figure 2B ). Of the caecal bile acids measured, LCA alone showed significant alterations after treatment with UDCA, and total caecal bile acid levels were similar in control (206 ± 15.5 nmol/g) and UDCAtreated mice (215 ± 18.0 nmol/g). Interestingly, when we tested its effects in Ussing chambers, we found that, in direct contrast to UDCA, LCA significantly potentiated agonist-induced secretory responses in T 84 cells ( Figure 2C ) and human tissue ( Figure   2D ).
In vivo administration of a metabolically stable UDCA analogue inhibits colonic secretory responses in mice. To further test the hypothesis that prosecretory effects of UDCA in vivo are due to its bacterial metabolism, we employed a non-metabolisable UDCA analogue, 6-methyl-UDCA (6-MUDCA). Methylation of UDCA in the 6-position sterically hinders bacterial 7-dehydroxylases, thereby preventing its metabolism to LCA (Roda et al., 1995) . We confirmed the stability of the compound in mice where, in contrast to UDCA, intraperitoneal administration of 6-MUDCA did not alter caecal LCA levels ( Figure 3A) . Treatment of voltage-clamped T 84 cells with 6-MUDCA inhibited both CCh-and FSK-stimulated secretory responses to a similar degree as did UDCA ( Figure 3B ), confirming that it retains the antisecretory actions of UDCA.
However, in contrast to our findings with UDCA, in vivo administration of 6-MUDCA significantly attenuated agonist-induced secretory responses in ex vivo colonic tissues ( Figure 3C ). Interestingly, 6-MUDCA did not alter SGLT-1 activity in ex vivo mouse jejunal tissues, suggesting the compound specifically inhibits epithelial secretory function ( Figure 3D ).
Sidedness of antisecretory actions of UDCA.
To further characterise antisecretory actions of UDCA on colonic epithelial cells, we examined the sidedness of responses to the bile acid. Basolateral addition of UDCA was more effective in inhibiting agonistinduced secretory responses than was apical addition ( Figure 4A ). Interestingly however, the taurine-conjugated derivative of UDCA (TUDCA; 500 M), which is unable to cross cell membranes unless a transporter is present, was ineffective when added apically, but was equipotent to UDCA when added basolaterally ( Figure 4B ). We also examined the sidedness of UDCA effects on agonist-induced secretory responses across sections of human colon in Ussing chambers. Similar to its effects in cultured T 84 cells, UDCA was more effective when applied basolaterally, with secretory responses to CCh being inhibited to 40.4 ± 8.1% of controls compared to 69.3 ± 14.1 % inhibition after apical addition (n = 4; p < 0.05). Figures 5A-B) . In contrast, UDCA did not alter FSK-stimulated apical Cl -currents which were 100.9 ± 22.2 % of control responses ( Figure 5C ).
UDCA inhibits
Finally, to determine if UDCA has its antisecretory effects by altering the surface expression of Na + /K + ATPase pumps and K + channels at the cell surface, we employed a cell surface biotinylation approach to quantify expression of these proteins in the basolateral membrane. However, these experiments revealed that there were no significant alterations in surface expression of either the Na + /K + ATPase  subunit or KCNN4 in UDCA-treated cells ( Figures 5D and 5E ).
DISCUSSION
It is well-established that dihydroxy bile acids stimulate intestinal fluid and electrolyte secretion and that their increased colonic delivery in conditions of bile acid malabsorption causes diarrhoea (Chadwick et al., 1979; Keely et al., 2007) . However, a notable exception is UDCA, which based on its lack of secretory actions in guinea pig, rabbit, and canine colon in vitro and in vivo, has been previously characterised as a "nonsecretory" bile acid (Mekjian et al., 1971; Rahban et al., 1980; Gelbmann et al., 1995) .
Here, we present new data to show that in addition to being non-secretory, UDCA also exerts potent antisecretory effects on colonic epithelial cells. The actions of UDCA were observed both in cultured cells and in pharmacologically-denervated human colonic tissue, suggesting they are due to a direct action of the bile acid on the epithelial cells. It was interesting to note that the time course by which UDCA has its antisecretory actions depends on the particular type of secretagogue in question, with inhibition of Ca 2+ -dependent responses occurring more rapidly than that of cAMP-dependent responses.
This suggests that different mechanisms might underlie the antisecretory effects of UDCA on Ca 2+ -and cAMP-dependent agonists. Although the concentrations at which UDCA has its antisecretory actions (50 µM-1 mM) might not normally occur in vivo (De Kok et al., 1999) , during conditions of bile acid malabsorption or when it is used therapeutically, levels of the bile acid increase significantly in the colonic lumen and serum (van Gorkom et al., 2002; Hess et al., 2004) .
Intriguingly, we found that, in contrast to its antisecretory actions in vitro, intraperitoneal injection of UDCA to mice potentiated secretagogue-induced responses across ex vivo colonic tissues. Such prosecretory effects of UDCA when administered in vivo may provide new insights into the diarrhoeal side effects that can occur when the bile acid is used therapeutically (Alberts et al., 2005) . While, the underlying cause of this diarrhoeal effect is not known, it has been hypothesised to be due to bacterially-mediated reepimerisation of the 7 beta-OH group of UDCA to give CDCA, which is prosecretory (Hempfling et al., 2003) . However, UDCA is preferentially metabolised in vivo to the monohydroxy bile acid, LCA, which has been shown to be the predominant colonic bile acid in humans treated with UDCA (van Gorkom et al., 2002) . We also found caecal LCA levels to increase dramatically upon administration of UDCA to mice. Although known to be a hepatotoxic bile acid, the effects of LCA on colonic transport function are poorly defined. Here, we found that LCA potentiates epithelial responses to secretagogues and it therefore may act to oppose the antisecretory actions of UDCA.
Thus, we hypothesised that metabolism to LCA might underlie the prosecretory effects of UDCA in vivo, and further that derivatives of UDCA, which cannot be metabolised by 7-dehydroxylation, should have antisecretory actions in vivo. To test this hypothesis we used 6-MUDCA, a 6-methylated derivative of UDCA that is completely resistant to bacterial dehydroxylation (Roda et al., 1995) , but which retains the antisecretory effects of UDCA in vitro. Upon administration to mice, 6-MUDCA did not alter caecal LCA levels and significantly inhibited secretagogue-induced responses across voltage-clamped colonic tissues. Thus, our data support the hypothesis that it is because of its metabolism to LCA that UDCA enhances colonic secretion in vivo, and that this effect may underlie the diarrhoeal side effects that occur when UDCA is used therapeutically for liver disease. Importantly, our data also suggest that non-metabolisable analogues of UDCA may be good candidates for development into a new class of antidiarrhoeal drug.
Although significant inhibition of agonist-induced responses was observed upon apical addition of UDCA, the bile acid was found to be more effective when added basolaterally. A similar pattern of responses to apical and basolateral UDCA was observed in voltage-clamped human colonic tissues. Interestingly, the taurine conjugate of UDCA, TUDCA, was only effective when applied basolaterally to T 84 monolayers.
TUDCA is more hydrophilic than UDCA, and unlike UDCA it cannot enter cells by passive diffusion across the lipid membrane. However, bile acid transporters are expressed on the basolateral membrane of colonic epithelia (Weihrauch et al., 2006) , which likely explains the increased efficacy of both TUDCA and UDCA when applied basolaterally. These data are consistent with our previous findings which show that conjugated bile acids do not cross the apical membrane of T 84 cells and that uptake of UDCA occurs more rapidly across the basolateral, than apical membrane (Keely et al., 2007) . Importantly, these data also suggest that UDCA, and its derivatives, must enter the cells before they can exert their antisecretory actions. Furthermore, conditions which disrupt tight junction integrity would be expected to result in enhanced epithelial delivery of UDCA or its conjugates to the basolateral membrane, thereby increasing their biological actions.
Using well-established approaches to specifically measure Na + /K + ATPase activity, K + channel currents, and Cl -channel currents, we found that UDCA significantly inhibited both Na + /K + ATPase activity and Ca 2+ -activated K + channel currents, but not FSKstimulated apical Cl -channel currents. Thus, upon entry into colonic epithelial cells, UDCA rapidly inhibits key transport proteins required for Cl -secretion to occur. We hypothesised that such effects of UDCA could be mediated by altered trafficking of transport proteins to the cell surface, and therefore carried out cell surface biotinylation analyses. However, we detected no reductions in the surface localisation of either Na + /K + ATPase pumps or K + channels after UDCA treatment, suggesting that the antisecretory effects of the bile acid are not mediated by altered trafficking of transport proteins to the cell surface. Thus, how UDCA inhibits the activity of Na + /K + ATPase pumps and K + channels remains to be determined but several possibilities exist. For example, UDCA may alter the generation of signals that activate these transport proteins or alternatively could alter their association with regulatory proteins. Several proteins are known to bind to and regulate Na + /K + ATPase activity, including FXYD proteins (Garty & Karlish, 2006) , translationally-controlled tumor protein (Jung et al., 2004) , and MONaKA (modulator of Na + /K + ATPase) (Mao et al., 2005) . Indeed, such regulatory proteins provide an attractive mechanism for inhibition of the Na + /K + ATPase pump, since many are expressed in a cell-specific manner and could explain why UDCA specifically inhibits Cl -secretory responses, while Na + absorptive processes, including electrogenic Na + absorption through ENaC and SGLT-1 activity, remain unaltered. Similarly, proteins that regulate the activity of KCNN4, the Ca 2+ -dependent K + channel, are known to exist and could represent targets for UDCA action (Joiner et al., 2001) . Future studies will focus on elucidating the molecular mechanisms by which UDCA inhibits the activities of these transport proteins and also to characterise the effects of UDCA on Na + /K + /2Cl -cotransporter activity, which is also a key component of the epithelial secretory pathway. 
